X4 Pharmaceuticals (XFOR) stock
XFOR's Quality Score rose 2 points on Mon, Oct 5, to -2. Up-day volume overtook down-day volume over 50 days (2 chart checks started).
Follow XFOR's trial news. Pro members can get an alert when X4 Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for XFOR, and how long its cash lasts
From X4 Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 9 quarters
Dilution on the horizon
- Shelf registration (S-3, filed May 6, 2026)
- At-the-market share sales program (S-3, filed May 6, 2026)
Insiders
President John Volpone sold 24,576 shares on Aug 12. 3 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 25 daysINOInovio Pharmaceuticals
INOINO-3107
- In 36 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 48 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 30% in 3 months, 26% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
6 more things pulling XFOR's score down, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last report it closed -10.6%.
What would turn XFOR's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
XFOR has 4 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1427.8
- MACD (12, 26, 9)Below signal
- 50-day average$3.79
- 200-day average$3.90
- ADX 1442.7
- Support$2.83
- Resistance$3.56
- Bollinger Bands (20, 2)Inside
- Volume0.5x
How XFOR ranks in Biotech
XFOR is #195 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
XENEOpen for its score
XERSOpen for its score
ZNTLOpen for its score
ZURAOpen for its score
XFOR4/14-3
When does XFOR report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 31 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Nov 5, 2025Before open | Before open | -6.3% | -10.6% | -11.1% |
Who is trading XFOR
XFOR insider trades
3 insiders sold $390K across 4 filings in the last 6 months. No open-market buys on record. The newest:
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of XFOR's score, with the points and the reason
- All 14 checks on XFOR and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on XFOR
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.